News | February 10, 2023
Lupin receives approval from USFDA for Glycopyrrolate Injection USP
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Subscribe To Our Newsletter & Stay Updated
